Here Are Morgan Stanley's Key Oncology Catalysts for 2025

Seeking AlphaDec 28 23:31

Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt

Simply Wall StDec 24 23:02

The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.

On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.

Gelonghui FinanceDec 24 14:58

Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website

BreakingsDec 24 01:12

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

BenzingaDec 23 22:00

SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?

Seeking AlphaDec 23 05:12